Latest Georgia News

Carbonxt is forecasting at least A$22 million of FY27 revenue after securing larger customer orders, but the growth plan remains tied to a delayed Kentucky facility and shareholder approval of a proposed balance sheet restructure. Cash stood at just A$0.7 million after a A$1.0 million operating outflow in the September quarter.

Krakatoa Resources has reported further high-grade gold and antimony intersections at its Zopkhito project in Georgia, including mineralisation outside the historical foreign resource estimate. The results advance drilling towards a maiden JORC-compliant resource, but the company’s cash position leaves little room for delay or funding surprises.

Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.

Carbonxt has added four US waste-to-energy facilities to its Reworld supply agreement, lifting annual Powdered Activated Carbon volumes by about 25% from January 2027. The expanded contract pushes the company’s FY27 revenue expectation to at least 40% above FY26, while Kentucky remains outside the forecast.

Pointerra3D delivered its strongest first-quarter customer receipts on record and returned to positive operating cash flow as enterprise deployments broadened across utilities, mining, transport and infrastructure. The ASX-listed software company ended September with A$1.95 million in cash, while several larger opportunities remain at proof-of-value or pending-award stages.

Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.

Eden Innovations has transformed its balance sheet, cutting interest-bearing liabilities from $16.97 million to negligible levels after year-end. But revenue fell 19%, the Group remained deeply loss-making and its auditor flagged a material uncertainty over going concern.

Krakatoa Resources advanced drilling at its flagship Zopkhito antimony-gold project in Georgia, but the exploration push more than doubled its annual loss and reduced cash to $739,459. The company subsequently raised $4 million, highlighting the funding needed to keep moving towards a maiden JORC-compliant resource.

Krakatoa Resources has reported a second batch of strong antimony and gold assays from drilling at its Zopkhito project in Georgia, led by a 5.61-metre interval grading 3.31g/t gold and 4.28% antimony. The results add support to mineralisation continuity, but the project remains at the exploration stage ahead of drilling, metallurgical work and a planned JORC resource estimate.

Krakatoa Resources has reported high-grade gold and antimony results from the first batch of its 2026 Zopkhito drilling assays, including 1.8 metres at 11.09 g/t gold and 3.56% antimony. The results support continuity at Vein 6 and identify mineralisation outside the project’s existing foreign estimate, but remain exploration results pending further drilling and a JORC assessment.

Artrya has launched its AI-powered Salix® platform commercially in the US, securing three foundation health systems and raising $80 million to fuel growth. With FDA clearance for its Coronary Plaque module and a pivotal clinical study underway, the company is poised for scaling revenues amid a strong balance sheet.

Eden Innovations Ltd trimmed its loss to $5 million in FY2026 while erasing bank debt and converting loans into equity, supported by property sales and capital raises.